[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK2344148T3 - Ernæringstilskud til forebyggelse eller moderering af knoglemarvsparalyse eller neutropæni under anti-cancerbehandling - Google Patents

Ernæringstilskud til forebyggelse eller moderering af knoglemarvsparalyse eller neutropæni under anti-cancerbehandling Download PDF

Info

Publication number
DK2344148T3
DK2344148T3 DK09792438.5T DK09792438T DK2344148T3 DK 2344148 T3 DK2344148 T3 DK 2344148T3 DK 09792438 T DK09792438 T DK 09792438T DK 2344148 T3 DK2344148 T3 DK 2344148T3
Authority
DK
Denmark
Prior art keywords
moderation
prevention
bone marrow
cancer treatment
nutritional supplements
Prior art date
Application number
DK09792438.5T
Other languages
English (en)
Inventor
Eduardo Schiffrin
Kevin Burke Miller
Dominique Brassart
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41382376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2344148(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Application granted granted Critical
Publication of DK2344148T3 publication Critical patent/DK2344148T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1783—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/125—Casei
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/151—Johnsonii
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/531—Lactis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/533—Longum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physics & Mathematics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pediatric Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DK09792438.5T 2008-09-19 2009-09-11 Ernæringstilskud til forebyggelse eller moderering af knoglemarvsparalyse eller neutropæni under anti-cancerbehandling DK2344148T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9825808P 2008-09-19 2008-09-19
PCT/US2009/056584 WO2010033425A2 (en) 2008-09-19 2009-09-11 Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment

Publications (1)

Publication Number Publication Date
DK2344148T3 true DK2344148T3 (da) 2016-02-29

Family

ID=41382376

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09792438.5T DK2344148T3 (da) 2008-09-19 2009-09-11 Ernæringstilskud til forebyggelse eller moderering af knoglemarvsparalyse eller neutropæni under anti-cancerbehandling

Country Status (14)

Country Link
US (2) US20110229447A1 (da)
EP (3) EP2344148B2 (da)
JP (4) JP5882735B2 (da)
CN (4) CN102215836B (da)
AU (2) AU2009293475A1 (da)
BR (2) BRPI0919847A2 (da)
CA (2) CA2737619A1 (da)
DK (1) DK2344148T3 (da)
ES (1) ES2556765T3 (da)
MX (2) MX2011002982A (da)
RU (2) RU2011115192A (da)
SG (1) SG194345A1 (da)
WO (2) WO2010033425A2 (da)
ZA (1) ZA201102908B (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2344148B2 (en) 2008-09-19 2024-05-08 Société des Produits Nestlé S.A. Nutritional support to prevent or moderate bone marrow paralysis during anti-cancer treatment
MX2012001362A (es) * 2009-07-31 2012-02-22 Nestec Sa Composicion nutricional para lactantes o mascotas alimentados con leche maternal con probioticos y nutrientes seleccionados.
WO2011019641A2 (en) * 2009-08-13 2011-02-17 Nestec S.A. Nutritional compositions including exogenous nucleotides
WO2011037712A2 (en) * 2009-09-25 2011-03-31 Nestec S.A. Nutritional compositions including theanine and exogenous nucleotides
WO2011139621A1 (en) * 2010-04-26 2011-11-10 Nestec S.A. Nutritional compositions and methods for weaning from parenteral nutrition to enteral nutrition
EP2676664B1 (en) * 2011-02-17 2017-06-21 EA Pharma Co., Ltd. Potentiator of antitumor activity of chemotherapeutic agent
ES2731636T3 (es) 2011-03-11 2019-11-18 Km Biologics Co Ltd Composición adyuvante que contiene citrulina
BR112013025047A2 (pt) * 2011-03-31 2017-02-14 Nestec Sa composições nutricionais para aumentar os níveis de arginina e métodos para usar as mesmas
WO2012138212A1 (en) * 2011-04-06 2012-10-11 N.V. Nutricia Food composition for intra-operative tube feeding
WO2012141575A1 (en) 2011-04-14 2012-10-18 N.V.Nutricia Combination of epa, dpa and/or dha with a chemotherapeutic agent
MY171851A (en) 2011-06-20 2019-11-04 Heinz Co Brands H J Llc Probiotic compositions and methods
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
TWI450692B (zh) * 2013-03-15 2014-09-01 En Otsuka Pharmaceutical Co 營養組成物
RU2018129984A (ru) 2013-05-10 2019-03-15 Эйч. Джей. ХАЙНЦ КОМПАНИ БРЕНДС ЛЛСи Пробиотики и способы их применения
SG11201600730QA (en) * 2013-07-31 2016-02-26 Ajinomoto Kk Agent for alleviating side effects in cancer chemotherapy
EP2876167A1 (en) * 2013-11-21 2015-05-27 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment
US11102994B2 (en) * 2014-08-21 2021-08-31 Clearfast Inc. Pre-operative carbohydrate-rich beverage composition and methods of treatment
US20170273326A1 (en) * 2014-08-29 2017-09-28 Wakamoto Pharmaceutical Co., Ltd. Lactic acid bacteria-containing composition
US20160101079A1 (en) * 2014-10-09 2016-04-14 Albert Crum Protective metallothionein analog compounds, their compositions and use thereof in the treatment of pathogenic diseases
BR112017014924A2 (pt) * 2015-02-13 2018-03-20 Nestec Sa Tratamento ou prevenção de caquexia induzida por cirurgia e/ou expressão de células supressoras de origem mieloide e citoquinas pró- inflamatórias
WO2016136942A1 (ja) * 2015-02-27 2016-09-01 株式会社明治 大腸炎抑制剤
EP3352586A4 (en) * 2015-09-21 2019-05-15 The Board Of Trustees Of The Leland Stanford Junior University NUTRITIONAL ANTICANCER TREATMENT
CN105617358A (zh) * 2015-12-29 2016-06-01 广州市戴菊科技发展有限公司 一种具有抗肿瘤功能的医用食品及其制备方法
JP2019511903A (ja) * 2016-02-19 2019-05-09 ナント ホールディングス アイピー エルエルシーＮａｎｔ Ｈｏｌｄｉｎｇｓ ＩＰ， ＬＬＣ 免疫原性調節の方法
RU2659240C2 (ru) * 2016-05-23 2018-06-29 федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный университет" (КемГУ) Способ получения функционального продукта питания для реабилитации онкологических больных
US11206861B2 (en) 2016-10-03 2021-12-28 Houn Simon Hsia Compositions and methods for enhancing cancer radiotherapy
JPWO2018079701A1 (ja) * 2016-10-28 2019-09-19 株式会社Ｎｒｌファーマ ラクトフェリン活性を有するタンパク質を含む、抗ガン治療補助剤
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
IL271327B2 (en) 2017-06-13 2024-11-01 Simon Hsia Houn Compositions for increasing tumor sensitivity to hyperthermic treatment
TW201906633A (zh) 2017-06-13 2019-02-16 夏滉 用於增進癌症化學療效之組合物及方法
US12029765B2 (en) 2017-06-13 2024-07-09 Houn Simon Hsia Compositions and methods for treating cancer
KR20200078467A (ko) 2017-06-13 2020-07-01 호운 사이먼 샤 암 방사선요법을 향상시키기 위한 조성물 및 방법
JP7266581B2 (ja) 2017-08-14 2023-04-28 アクセラ・ヘルス・インコーポレイテッド 肝疾患の治療のためのアミノ酸組成物
CA3084319A1 (en) 2017-12-11 2019-06-20 Filtricine, Inc. Compositions, methods, kits and systems for cancer treatment and metabolic intervention therapy
GB201721833D0 (en) * 2017-12-22 2018-02-07 Cancer Research Tech Ltd Fusion proteins
WO2019169179A1 (en) * 2018-02-28 2019-09-06 Shafer Kim Augmenting efficacy of cancer therapies using probiotic based compositions
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
CN111714616A (zh) * 2019-07-17 2020-09-29 江苏西宏生物医药有限公司 一种用于抗肿瘤的组合物
CN110463990A (zh) * 2019-07-24 2019-11-19 浙江禾健生营养科技有限公司 一种肿瘤免疫增强营养食品及其制备方法
KR102529206B1 (ko) * 2019-12-20 2023-05-08 충북대학교 산학협력단 신규한 락토바실러스 루테리 ｄｂ２ 균주 및 이의 용도
WO2021146647A1 (en) * 2020-01-17 2021-07-22 Second Genome, Inc. Methods and compositions for treating cancer
TWI773166B (zh) * 2020-07-29 2022-08-01 景岳生物科技股份有限公司 增加化療藥物吉西他濱抑制胰臟癌效果之益生菌組合物及其用途
CN112957351B (zh) * 2021-03-17 2022-03-11 南通大学 ω-3多不饱和脂肪酸和L-丝氨酸在制备乳腺癌化疗药物的增效剂中的应用
CN115067518A (zh) * 2022-06-07 2022-09-20 广东特芯生物科技有限公司 一种用于提高肿瘤患者免疫力的组合物
CN117398451A (zh) * 2023-11-13 2024-01-16 海南华研胶原科技股份有限公司 一种增强免疫力的胶原蛋白肽制剂的制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231085A (en) † 1988-10-31 1993-07-27 Sandoz Ltd. Compositions and methods for the enhancement of host defense mechanisms
US5576351A (en) * 1989-12-29 1996-11-19 Mcgaw, Inc. Use of arginine as an immunostimulator
AUPN271295A0 (en) * 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
US5330972A (en) * 1993-05-28 1994-07-19 Abbott Laboratories Method of impeding apoptosis of CD4 cells in persons infected with human immunodeficiency virus
ES2243965T3 (es) 1996-07-09 2005-12-01 Societe Des Produits Nestle S.A. Procedimiento de secado mediante pulverizacion.
DE19630230A1 (de) * 1996-07-26 1998-01-29 Bayer Ag Herstellung immunstimulierender Mittel auf Basis von Propionibakterien
US6210700B1 (en) 1997-01-14 2001-04-03 Novartis Nutrition Ag Enhancement of transplant graft survival through nutritional immunomodulation with omega-9 fatty acid dietary supplement therapy
GB2323030A (en) * 1997-03-12 1998-09-16 Essential Nutrition Ltd Dietary supplements for immunocompromised patients
AU2089297A (en) * 1997-03-17 1998-10-12 Yun K. Tam Composition for prevention of hepatic steatosis
DE69841826D1 (de) * 1997-08-21 2010-09-23 New Zealand Dairy Board Immunitätsteigernde milchsäurebakterien
JPH11180891A (ja) * 1997-12-25 1999-07-06 Dai Ichi Seiyaku Co Ltd 抗細胞死剤
ATE264093T1 (de) * 1998-07-16 2004-04-15 Aaron Tabor Sojazubereitungen und deren verwendung zur gesundheitsförderung
US9486429B2 (en) † 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
FR2802212B1 (fr) 1999-12-13 2002-03-01 Agronomique Inst Nat Rech Procede pour l'obtention d'une poudre contenant des micro-organismes viables, poudre obtenue selon ce procede et dispositif pour sa mise en oeuvre
US6420342B1 (en) * 2000-05-08 2002-07-16 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof
US20020165178A1 (en) * 2000-06-28 2002-11-07 Christian Schetter Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia
JP2004524820A (ja) * 2000-09-15 2004-08-19 ユニバーシティー オブ コネティカット ヘルス センター 熱ショック／ストレスタンパク質−ペプチド複合体
JP4398642B2 (ja) 2001-02-19 2010-01-13 ソシエテ・デ・プロデュイ・ネスレ・エス・アー プロバイオティック含有摂取製品
CN100589845C (zh) * 2001-03-07 2010-02-17 麦康公司 用于治疗癌症的抗新血管系统制剂
US20030068385A1 (en) * 2001-03-23 2003-04-10 Moyer Mary Pat Accelerated action fatty acid (AAFA) promotes health of normal tissues and minimizes the toxic side effects of chemotherapy
US6864230B2 (en) * 2001-07-31 2005-03-08 Novartis Nutrition Ag Glutamine rich dietary composition
CA2471968C (en) * 2001-10-06 2013-07-23 Merial Limited Immunostimulatory nucleic acids and use thereof
US20030105104A1 (en) † 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US20040082504A1 (en) * 2002-05-10 2004-04-29 Atul Varadhachary Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
CA2493764C (en) * 2002-08-01 2011-05-24 Aesgen, Inc. Improved treatment of cancer with glutamine
US7674482B2 (en) * 2002-08-27 2010-03-09 Targeted Medical Pharma Inc. Method and compositions for potentiating pharmaceuticals with amino acid based medical foods
DE10244397A1 (de) * 2002-09-24 2004-04-01 Basf Ag Cholinascorbat-Formulierungen
CN1480135A (zh) * 2003-07-15 2004-03-10 郭凌云 由左旋－茶氨酸为有效组分生产不同剂型的药物或保健品
US7186517B2 (en) * 2003-08-01 2007-03-06 Aesgen, Inc. Compositions and methods for monitoring breast cancer treatment
BRPI0415480B1 (pt) * 2003-10-16 2019-09-17 Nestec S.A. Composição nutricional contra efeitos colaterais de quimioterapia ou radioterapia
US7025996B1 (en) * 2003-10-21 2006-04-11 Vesselin Danailov Miladinov Dietary supplement for medical patients
CN101022821B (zh) * 2004-07-19 2014-01-29 纽崔西亚公司 天冬氨酸用于调节血中葡萄糖水平的用途
CN1709235A (zh) * 2005-06-01 2005-12-21 王兰周 醋酸精氨酸注射液及其制造方法
DE102005052367A1 (de) 2005-10-31 2007-05-03 Robert Bosch Gmbh Messgerät und Verfahren zur Ortung von in einem Medium eingeschlossenen Objekten mittels elektromagnetischer HF-Signale
EP2612666A3 (en) 2006-04-04 2013-10-02 Nestec S.A. Treatments using citrulline
GB0611131D0 (en) * 2006-06-06 2006-07-19 Neo Inhalation Technologies Lt Nicotine inhalation therapies - smoking cessation and other medical uses
CN101091794A (zh) * 2006-06-19 2007-12-26 博尔诚（北京）科技有限公司 用于预防和治疗转移性肿瘤的组合物
US20100152107A1 (en) * 2006-10-19 2010-06-17 Nestec S.A. Long-term feed - cancer patient
EP2344148B2 (en) * 2008-09-19 2024-05-08 Société des Produits Nestlé S.A. Nutritional support to prevent or moderate bone marrow paralysis during anti-cancer treatment

Also Published As

Publication number Publication date
EP2344147A2 (en) 2011-07-20
JP2015143239A (ja) 2015-08-06
WO2010033424A2 (en) 2010-03-25
AU2009293475A1 (en) 2010-03-25
CN102215836A (zh) 2011-10-12
CA2737619A1 (en) 2010-03-25
CA2736747C (en) 2018-02-27
JP6030303B2 (ja) 2016-11-24
JP2012502997A (ja) 2012-02-02
WO2010033424A3 (en) 2010-09-23
RU2011115184A (ru) 2012-10-27
ZA201102908B (en) 2014-10-29
EP2344148B2 (en) 2024-05-08
SG194345A1 (en) 2013-11-29
CN105876780A (zh) 2016-08-24
US20110229521A1 (en) 2011-09-22
CN102164595A (zh) 2011-08-24
WO2010033425A3 (en) 2010-09-23
JP5882735B2 (ja) 2016-03-09
CA2736747A1 (en) 2010-03-25
EP2344148A2 (en) 2011-07-20
EP3011843A1 (en) 2016-04-27
BRPI0919409A2 (pt) 2015-12-15
BRPI0919847A2 (pt) 2015-12-15
ES2556765T3 (es) 2016-01-20
WO2010033425A2 (en) 2010-03-25
MX2011002983A (es) 2011-04-11
JP2015147770A (ja) 2015-08-20
MX2011002982A (es) 2011-04-11
CN102215836B (zh) 2015-07-08
AU2009293474A1 (en) 2010-03-25
RU2011115192A (ru) 2012-10-27
EP2344148B1 (en) 2015-10-21
CN103355668A (zh) 2013-10-23
JP2012502996A (ja) 2012-02-02
US20110229447A1 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
DK2344148T3 (da) Ernæringstilskud til forebyggelse eller moderering af knoglemarvsparalyse eller neutropæni under anti-cancerbehandling
BRPI0915149A2 (pt) Composição nutricional, e usos de uma composição, e de um produto derivado de leite
HK1172516A1 (en) Nutritional composition for promoting gut microbiota balance and health
DK2588154T3 (da) Sammensætning omfattende calciumphosphat, sulfatpulvere eller dmb anvendt i behandlingen af degenerative knogletilstande
EP2446031A4 (en) ALKYLGLYCOSIDE STABILIZING COMPOSITIONS AND METHODS OF USE THEREOF
HK1180239A1 (zh) 用於組織礦化的微膠囊化組合物和方法
ZA200906390B (en) Compositions and methods for promoting bone development
EP2589627A4 (en) OIL-IN-WATER SILICONE EMULSION COMPOSITION
PL2405835T3 (pl) Urządzenie do odbudowy kostnej kręgosłupa
EP2306913A4 (en) BONE ANCHOR FOR ORTHOPEDIC APPLICATIONS
HK1216842A1 (zh) 對於穩定含有蛋白質的製劑有用的組合物和方法
BR112012003092A2 (pt) composições e métodos para implantação de tecido adiposo processado e produtos de tecido adiposo processados.
EP2604115A4 (en) COMPOSITION FOR COMBATING PLANT DISEASES AND APPLYING THEM
DK2227539T3 (da) Sammensætning til menneske- og/eller dyreernæring, anvendelser deraf og gær
DK2508083T3 (da) Biologisk aktivt kosttilskud til profylakse af osteoporose sygdomme
IL219984A0 (en) Circulation of components during microfluidizaion and/or homogenization emulsions
DK2569019T3 (da) Sammensætninger, fremgangsmåder og systemer til syntesen og anvendelsen af billeddannelsesmidler
BRPI0912089A2 (pt) composições de fluoropolímero misturadas
EP2604117A4 (en) COMPOSITION FOR CONTROLLING PLANT DISEASES AND USE THEREOF
EP2549997A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NON ALCOHOLIC HEALING STEATOSIS AND METHOD FOR THE PREVENTION OR TREATMENT OF NON ALCOHOLIC HEALING STEATOSIS USING THE SAME
SI3586826T1 (sl) Sestavki in postopki za stabilizacijo formulacij, ki vsebujejo beljakovine
BRPI0914023A2 (pt) composição nutricional e método para fornecer uma nutrição
EP2415458A4 (en) OIL-IN-WATER EMULSION COMPOUND
BR112013013777A2 (pt) método não terapêutico e composição nutricional para bebês
HK1188122A1 (zh) 牛蒡子苷元預防或治療骨髓抑制的用途